Phosphoinositide 3-kinase inhibitors with a zinc binding moiety

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9725461
APP PUB NO 20150203509A1
SERIAL NO

14539327

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • CURIS, INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Cai, Xiong Bedford, US 100 1263
Lai, Chengjung Belmont, US 21 102
Qian, Changgeng Wayland, US 73 747
Zhai, Haixaio Bedford, US 1 10

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 8, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 8, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00